Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 6:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: vehicle control Clear all
Completed Phase 2 Interventional

Multicenter Study of the Efficacy and Safety of Luliconazole Cream in Tinea Pedis (Athlete's Foot)

NCT00869336
View directory record Official record
Conditions
Tinea Pedis
Interventions
Luliconazole Cream 1% - 2 wks, Placebo Comparator -2 wks, Luliconazole Cream 1% - 4 wks, Placebo Comparator - 4 wks
Drug
Lead sponsor
Tinea Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
4
States / cities
Fridley, Minnesota • Portland, Oregon • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2011 · Synced Sep 25, 2026, 6:26 AM EDT
Not listed Phase 1Phase 2 Interventional

Intranasal Neuropeptide Y in Clinical Trial in Level Two Trauma Patients for PTSD and Acute Stress Disorder

NCT04071600
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic, Stress Disorders, Traumatic, Acute
Interventions
Neuropeptide Y, Placebo
Drug · Other
Lead sponsor
New York Medical College
Other
Eligibility
18 Years to 65 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 25, 2026, 6:26 AM EDT
Completed Phase 2 Interventional Results available

A Study of Safety and Efficacy of UNR844 Chloride (UNR844-Cl) Eye Drops in Subjects With Presbyopia.

NCT03809611
View directory record Official record
Conditions
Presbyopia
Interventions
UNR844-Cl, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years to 65 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
14
States / cities
Mission Hills, California • Newport Beach, California • Largo, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Sep 25, 2026, 6:26 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of KPI-121 in Subjects With DED

NCT03616899
View directory record Official record
Conditions
Kerato Conjunctivitis Sicca
Interventions
KPI-121 Ophthalmic Suspension, Vehicle
Drug
Lead sponsor
Kala Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
81
States / cities
Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Sep 25, 2026, 6:26 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis

NCT06238817
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib Cream, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
18
States / cities
Little Rock, Arkansas • Fountain Valley, California • Fremont, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 25, 2026, 6:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Epigenetic Effects of Diesel Exhaust and Ozone Exposure

NCT01492517
View directory record Official record
Conditions
Exposure to Pollution, Inhalation of Ozone
Interventions
Ozone exposure, Diesel exhaust, Ozone18, Clean Air
Other
Lead sponsor
Environmental Protection Agency (EPA)
Federal
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 17, 2016 · Synced Sep 25, 2026, 6:26 AM EDT
Completed Phase 2 Interventional Results available

A Dose Ranging Vehicle Controlled Study to Determine the Safety and Efficacy of Permethrin Foam, 5% and Permethrin Foam, 4% for the Treatment of Scabies

NCT02094716
View directory record Official record
Conditions
Scabies
Interventions
Permethrin Foam 4%, Permethrin Foam 5%, Vehicle Foam
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
6 Months and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
5
States / cities
Fremont, California • Los Angeles, California • Hialeah, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Sep 25, 2026, 6:26 AM EDT
Completed Phase 3 Interventional Results available

A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004)

NCT03285490
View directory record Official record
Conditions
Actinic Keratosis
Interventions
KX2-391 Ointment 1%, Placebo
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
18 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
30
States / cities
Phoenix, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Sep 25, 2026, 6:26 AM EDT
Completed Phase 2 Interventional Results available

A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.

NCT05375955
View directory record Official record
Conditions
Atopic Dermatitis, Plaque Psoriasis
Interventions
PF-07038124 ointment 0.01%, Vehicle ointment, PF-07038124 ointment 0.03%, PF-07038124 ointment 0.06%
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
23
States / cities
Encinitas, California • Los Angeles, California • Cape Coral, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Sep 25, 2026, 6:26 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of DUR-928 Topical Solution in Subjects With Plaque Psoriasis

NCT03837743
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
DUR-928 Topical Solution, Vehicle Topical Solution
Drug
Lead sponsor
Durect
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
San Diego, California • Miami, Florida • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Sep 25, 2026, 6:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Safety Study of TG100801 Eye Drops in Healthy Volunteers

NCT00414999
View directory record Official record
Conditions
Macular Degeneration, Diabetic Retinopathy
Interventions
TG100801
Drug
Lead sponsor
TargeGen
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2007 · Synced Sep 25, 2026, 6:26 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate AI-09 In Participants With Glabellar Lines

NCT07321834
View directory record Official record
Conditions
Glabellar Lines
Interventions
AI-09 Ready Use Injectable Botulinum Toxin, Vehicle
Biological
Lead sponsor
Eirion Therapeutics Inc.
Industry
Eligibility
20 Years to 70 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Aventura, Florida • West Palm Beach, Florida • New Orleans, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 25, 2026, 6:26 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea

NCT01555463
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
Azelaic acid foam, 15% (BAY39-6251), Vehicle foam
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
961 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
49
States / cities
Birmingham, Alabama • Fremont, California • Los Angeles, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Sep 25, 2026, 6:26 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study of SST-0225 Topical Ibuprofen Cream in the Treatment of Delayed Onset Muscle Soreness (DOMS)

NCT02597634
View directory record Official record
Conditions
Delayed Onset Muscle Soreness, DOMS
Interventions
SST-0225, Placebo
Drug
Lead sponsor
Strategic Science & Technologies, LLC
Industry
Eligibility
16 Years to 65 Years
Enrollment
156 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
3
States / cities
Hollywood, Florida • South Miami, Florida • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 12, 2016 · Synced Sep 25, 2026, 6:26 AM EDT
Completed Phase 3 Interventional Results available

CHAMP: Study of NVK-002 in Children With Myopia

NCT03350620
View directory record Official record
Conditions
Myopia
Interventions
NVK-002 Concentration 1, NVK-002 Concentration 2, Placebo
Drug
Lead sponsor
Vyluma, Inc.
Industry
Eligibility
3 Years to 17 Years
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
20
States / cities
Tucson, Arizona • Berkeley, California • Fullerton, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Sep 25, 2026, 6:26 AM EDT
Completed Phase 2 Interventional Results available

A Double Blinded, Prospective, Randomized, Vehicle Controlled Multi-center Study of Photodynamic Therapy With Visonac® Cream in Patients With Acne Vulgaris

NCT01347879
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Visonac PDT, Vehicle cream with PDT
Drug
Lead sponsor
Photocure
Industry
Eligibility
12 Years to 35 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
15
States / cities
Oceanside, California • San Diego, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2014 · Synced Sep 25, 2026, 6:26 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Driver Education Research Study

NCT06413927
View directory record Official record
Conditions
Risk Reduction Behavior, Injuries, Accident, Traffic, Development, Adolescent
Interventions
Online Vehicle and Driver Safety Education, Online Driver Skills Training, Behind-the-Wheel Driver Training
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
16 Years to 17 Years
Enrollment
1,300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 25, 2026, 6:26 AM EDT
Completed Phase 4 Interventional Results available

A Clinical Study With Fluticasone Furoate Nasal Spray And Vehicle Placebo For The Treatment Of Perennial (Year-round) Allergic Rhinitis

NCT00682643
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
fluticasone furoate nasal spray, vehicle placebo nasal spray
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
56
States / cities
Oxford, Alabama • Little Rock, Arkansas • Fresno, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Sep 25, 2026, 6:26 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Gene Therapy for Painful Diabetic Neuropathy

NCT02427464
View directory record Official record
Conditions
Painful Diabetic Neuropathy, Diabetic Neuropathy, Painful
Interventions
Engensis (VM202), placebo
Biological · Other
Lead sponsor
Helixmith Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
25
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Gatos, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Sep 25, 2026, 6:26 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis

NCT00361881
View directory record Official record
Conditions
Herpes Labialis
Interventions
ME-609, acyclovir in ME-609 vehicle, Vehicle
Drug
Lead sponsor
Medivir
Industry
Eligibility
18 Years and older
Enrollment
1,443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Mt. Pleasant, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 17, 2008 · Synced Sep 25, 2026, 6:26 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders

NCT02929823
View directory record Official record
Conditions
Corneal Epithelial Disorders
Interventions
High Dose SJP-0035 Ophthalmic Solution, Low Dose SJP-0035 Ophthalmic Solution, Vehicle of SJP-0035 Ophthalmic solution
Drug
Lead sponsor
Senju Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
19
States / cities
Little Rock, Arkansas • Glendora, California • Lancaster, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Sep 25, 2026, 6:26 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess Safety and Clinical Activity of Local MBN-101 in Treatment of Infected Bone Sites

NCT02436876
View directory record Official record
Conditions
Bacterial Infection
Interventions
MBN-101, Placebo
Drug · Other
Lead sponsor
Microbion Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
6
States / cities
San Francisco, California • Baltimore, Maryland • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Sep 25, 2026, 6:26 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts

NCT02971891
View directory record Official record
Conditions
Cutaneous Common Warts
Interventions
CLS006 (Furosemide) Topical Gel, Vehicle Topical Gel
Drug
Lead sponsor
Maruho Co., Ltd.
Industry
Eligibility
2 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
30
States / cities
Mobile, Alabama • Glendale, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Sep 25, 2026, 6:26 AM EDT
Not listed Phase 2 Interventional

A Trial to Evaluate the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratosis

NCT06108024
View directory record Official record
Conditions
Seborrheic Keratosis
Interventions
SM-020 gel 1.0%, Vehicle gel
Drug
Lead sponsor
DermBiont, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Coral Gables, Florida • New Brighton, Minnesota • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Sep 25, 2026, 6:26 AM EDT